Evidence map›Paper›PMID 42270676›Full record

ArticleNature communications2026

O-linked glycan-dependent gating of TPC2 controls lysosomal excitability and organelle remodeling.

Alice Lin, Neng-Yu Lin, Marco Keller, Ramona Schütz, Yi-Zhen Wu, William Burton, Novelyn Putri Kinanti, Chi-Yuan Yao, Nicole Urban, Ya-Wen Liu and 5 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Alice Lin *Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan.ORCID 0009-0008-8372-9994
Neng-Yu Lin *Graduate Institute of Anatomy and Cell Biology, National Taiwan University College of Medicine, Taipei, Taiwan.
Marco KellerDepartment of Pharmacy, Center for Drug Research, Ludwig-Maximilians University, Munich, Germany.ORCID 0000-0003-4792-3980
Ramona SchützDepartment of Pharmacy, Center for Drug Research, Ludwig-Maximilians University, Munich, Germany.ORCID 0000-0003-1282-6662
Yi-Zhen WuDepartment of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan.
William BurtonDepartment of Pharmacology, University of Oxford, Oxford, UK.ORCID 0009-0000-3984-548X
Novelyn Putri KinantiDepartment of Biomedical Sciences and Engineering, Tzu Chi University, Hualien, Taiwan.
Chi-Yuan YaoDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0001-5052-9445
Nicole UrbanRudolf-Boehm-Institute of Pharmacology and Toxicology, Leipzig University, Leipzig, Germany.ORCID 0000-0001-5516-7922
Ya-Wen LiuInstitute of Molecular Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.ORCID 0000-0003-0180-4142
Franz BracherDepartment of Pharmacy, Center for Drug Research, Ludwig-Maximilians University, Munich, Germany.ORCID 0000-0003-0009-8629
Antony GalioneDepartment of Pharmacology, University of Oxford, Oxford, UK.ORCID 0000-0002-4132-7646
Hao-Jen HsuDepartment of Biomedical Sciences and Engineering, Tzu Chi University, Hualien, Taiwan.ORCID 0000-0001-6096-7481
Ching-Ying KuoDepartment of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Cheng-Chang ChenDepartment of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan. chenchengchang@ntu.edu.tw.ORCID 0000-0003-1282-4026

Funding

Ministry of Science and Technology, Taiwan (Ministry of Science and Technology of Taiwan) NSTC 114-2320-B-002-022National Health Research Institutes (NHRI) NHRI-EX113-11119SCNational Taiwan University (NTU) NTU-114L7857
6 · The paper itself

Abstract

Two-pore channel 2 (TPC2) is a lysosomal cation channel involved in calcium and sodium signaling and membrane remodeling. Its dysfunction has been linked to diseases including viral infections, neurodegenerative disorders, and cancer. Here, we identify mucin-type O-linked glycosylation at two conserved luminal residues of TPC2, Ser612 and Ser613, as a structural gating brake. Combining structure-guided mutagenesis, lysosomal patch-clamp recordings, calcium nanodomain imaging, molecular dynamics simulations, and small-molecule modulation, we show that genetic, enzymatic, or pharmacological glycan removal enhances basal and ligand-evoked TPC2 activity. This hyperactivation induces lysosomal tubulation, increases vesicle mobility, and promotes TPC2 clustering. In cancer-related models, glycan-deficient TPC2 also increases cell migration, which can be reversed by inhibitors such as tetrandrine and SC-3. These findings establish luminal glycosylation as a key post-translational regulator of TPC2 gating and reveal a mechanism by which ion channel activity controls lysosomal architecture and disease-relevant cell behavior.

Indexed as

Calcium ChannelsIon Channel GatingLysosomesPolysaccharidesAnimalsCalciumCell MovementGlycosylationHEK293 CellsHumansMolecular Dynamics SimulationTwo-Pore ChannelsCalciumCalcium ChannelsPolysaccharidesTPCN2 protein, humanTwo-Pore Channels

Identifiers

PMID42270676
PMCPMC13402618

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.